Licensing Blog

Indiana Moves Forward in Psychedelic Therapy

Indiana Moves Forward in Psychedelic Therapy

Governor Holcomb of Indiana recently signed House Bill (HB) 1259 into law, marking a significant leap forward in the state’s approach to mental health treatment. This legislation funds clinical trials investigating the therapeutic potential of psilocybin in addressing various mental health conditions, particularly among veterans and first responders.

The Bill

HB 1259 challenges the conventional classification of psilocybin as a Schedule I drug by recognizing its proven medical benefits. The bill’s emphasis on supporting research underscores a shift in understanding and acknowledging the potential of psychedelics in mental health treatment.

The Application

The application process outlined in the legislation sets a structured framework for researchers interested in studying psilocybin’s effects. To qualify for funding, researchers must submit proposals to Indiana’s Department of Health, detailing their intended studies on psilocybin’s efficacy in treating PTSD, anxiety, depression, Bipolar disorder, chronic pain, alcohol use disorder, tobacco use disorder, and other specified conditions. These studies must compare psilocybin’s effectiveness against existing treatment options.

By July 1st, 2024, officials are tasked with establishing a transparent process for administering funds and processing applications. This meticulous approach ensures accountability and fosters responsible research practices.

Once funding is secured, research institutions undertaking clinical studies must adhere to specific guidelines. These include the inclusion of veterans and first responders in study samples, rigorous evaluation of psilocybin’s efficacy, comparison with current treatment options, and conducting mental health evaluations of participants before their inclusion in the study.

Indiana’s Progress: Psilocybin v. Cannabis

The passage of Senate Bill 139 earlier this year further solidifies Indiana’s commitment to exploring the therapeutic potential of psychedelics. This bill, unanimously approved by Indiana’s Senate Panel, aims to establish the therapeutic psilocybin research fund and sets forth clinical study requirements. Indiana’s stance on psychedelics research indicates a progressive approach to mental health care. To learn more about SB 139, visit this article.

On the other hand, Indiana’s policy reform in the cannabis realm is not as progressive, which is rather surprising. In fact, during the 2023 legislative session, the only bill to receive a committee hearing in the House was a decriminalization bill. House Bill (HB) 1397 aimed to decriminalize mere possession of two ounces or less of marijuana. Unfortunately, it didn’t advance outside the committee. This resulted because, despite strong public support for reform, supported by an 85% approval rate among constituents, Republican lawmakers in Indiana have yet to embrace cannabis legalization. The failure of HB 1397 highlights the political divide, and lack of progress, on cannabis policy in the state.


As Indiana continues on a new chapter of research and exploration into psychedelics, the state is facing a pivotal moment of opportunity. However, before any substantial progress can be made, lawmakers have to reconcile their differences about the benefits of psychedelics in therapeutic settings.

To discuss your options in Indiana’s psychedelic market, contact our Team today!